Research Article
[Retracted] Prognosis and Therapeutic Efficacy Prediction of Adrenocortical Carcinoma Based on a Necroptosis-Associated Gene Signature
Figure 5
The immunocyte infiltration landscape of ACC was revealed by ssGSEA, and a necroptosis-associated gene signature was validated as a predictor for both immunotherapy and chemotherapy in ACC. (a) Immunocyte infiltration landscape for each patient depiction via a heatmap. (b) Response prediction of immunotherapy via SubMap analysis with an ACC cohort containing both patients who received and did not receive anti-PD1 or anti-CTLA4 therapy. (c) Comparison of NAGs among patients with CP/RP, PD, and SD in a checkmate cohort. (d) Comparison of chemotherapy response between high and low NAGs groups. The IC50 was employed as the evaluation indicator, and a higher IC50 represented lower drug sensitivity. (e) Drug-induced change in NAGs across NCI-60 cell lines after exposure to cisplatin for 2, 6, and 24 h. (f) Drug-induced change in NAGs across NCI-60 cell lines after exposure to gemcitabine for 2, 6, and 24 h.
(a) |
(b) |
(c) |
(d) |
(e) |
(f) |